Relevant Articles About NSCLC Research and Clinical Trials
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Privacy Policy
KEY TAKEAWAYS The study aimed to assess serum fibronectin and gene polymorphisms as predictors of recurrence and treatment response in patients with NMIBC on BCG therapy. Researchers found elevated serum fibronectin predicts early recurrence in NMIBC but not BCG...
KEY TAKEAWAYS The study aimed to estimate the global prevalence of GIM through a systematic review and meta-analysis. The results showed the global prevalence of GIM is high, requiring further investigation and attention. Sara Soroorikia and the team aimed to...
KEY TAKEAWAYS The study aimed to investigate the role of CD247 and CD4 expression in TNBC prognosis. The results showed low CD247 and CD4 expression predicts poor outcomes in patients with TNBC. Ankit Pateriya and the team aimed to evaluate the prognostic...
The PROPHETIC trial aimed to develop and validate plasma proteomics-based models for predicting treatment-related toxicity in patients with NSCLC. Researchers identified distinct protein …
The APOLO phase II trial aimed to examine induction chemo-immunotherapy + chemo-radiotherapy and maintenance immunotherapy in patients with stage III NSCLC. Researchers suggested …
The FLOWERS phase II trial aimed to evaluate osimertinib with or without savolitinib as first-line treatment in patients with EGFR-mutant, MET-aberrant, advanced NSCLC. …
Humanized immunodeficient mice serve as critical models for investigating the functional interplay between transplanted human cells and a pre-reconstituted human immune system. These models facilitate the study of molecular and cellular pathogenic mechanisms and enable …
Background Chimeric antigen receptor (CAR) T-cell therapy has demonstrated significant benefits in the treatment of relapsed/refractory multiple myeloma (RRMM). However, these outcomes can be compromised by severe complications, including cytokine release syndrome, immune effector cell-associated neurotoxicity …
Background Immune-related adverse events (irAEs) are major barriers of clinical management and further development of immune checkpoint inhibitors (ICIs) for cancer therapy. Therefore, biomarkers associated with the onset of severe irAEs are needed. In this study, …
Background Adoptive cell transfer (ACT) shows promise as an immunotherapy for melanoma and other cancers. However, there are several challenges associated with ACT such as the logistical complexity and inconsistency when using patient-derived antigen-presenting cells for …